Skip to main content

Apixaban VS Rivaroxaban

 






🚨 Apixaban shows a significantly lower bleeding risk than rivaroxaban — what does the evidence say?

In the management of acute venous thromboembolism (VTE), selecting the right anticoagulant is critical — especially when balancing efficacy and safety.

A large randomized trial involving 2760 patients compared Apixaban and Rivaroxaban over a 3-month treatment period.

📊 Key Findings:

• Clinically relevant bleeding occurred in:
✔ 3.3% with apixaban
✔ 7.1% with rivaroxaban

➡ This reflects a 54% lower risk of bleeding with apixaban (P < 0.001)

• Death from any cause was low in both groups:
• 0.1% (apixaban) vs 0.3% (rivaroxaban)

• Serious adverse events were comparable between the two treatments.

💡 Clinical Takeaway:
This study highlights that apixaban may offer a safer bleeding profile compared to rivaroxaban in patients with acute VTE, while maintaining similar overall outcomes.

🔍 However, individual patient factors and clinical judgment remain essential in anticoagulant selection.

💬 Which anticoagulant do you prefer in your practice — and why?
Source : CLICK HERE

Comments

Popular posts from this blog

Curated Compendium of Drug Discovery

  Drug discovery is a multidisciplinary process that integrates biology, chemistry, pharmacology , and cutting-edge technologies to identify and develop new therapeutic agents. From target identification to lead optimization and clinical evaluation, each stage requires precision, innovation, and collaboration. A curated list of drug discovery resources provides researchers, students, and professionals with a structured pathway to explore advancements, tools, and strategies that shape modern therapeutics. This compilation serves as a gateway to understanding the evolution of drug discovery, recent breakthroughs, and future directions, fostering knowledge-sharing and accelerating translational research. Databases and Chemical Libraries General Compound Libraries DrugBank  - Comprehensive data on approved and investigational drugs. ZINC  - Free compounds for screening. ChemSpider  - Chemical structures and data. DrugSpaceX  - Chemical and biological spaces. Mcule ...

Understanding NMR Spectroscopy and Chemical Shift Ranges for Functional Groups

  Nuclear Magnetic Resonance ( NMR ) spectroscopy is one of the most powerful analytical tools in pharmaceutical chemistry. It helps chemists determine the structure, purity, and chemical environment of molecules by analyzing the behavior of nuclei (commonly ¹H or ¹³C ) when exposed to a strong magnetic field. In proton NMR ( ¹H-NMR ), the chemical shift (δ, in ppm) provides information about the type of hydrogen atoms present in a compound and their surrounding electronic environment. Depending on nearby atoms and functional groups, signals appear in specific regions of the spectrum — often referred to as upfield (shielded, lower δ values) or downfield (deshielded, higher δ values). The image above summarizes the characteristic δ ranges for different functional groups in ¹H-NMR. Let us break it down systematically: 1. Downfield Region (δ 12 – 6 ppm) Hydrogens in this region are strongly deshielded due to electronegative atoms or π-bond systems. Carboxylic Acids (–COOH) : δ 1...

Pushing the boundaries of computational drug discovery at Isomorphic Labs

  The Isomorphic Labs Drug Design Engine (IsoDDE) has unlocked a new frontier in in-silico drug design, representing a significant evolution beyond AlphaFold 3. What IsoDDE delivers: 🔹 Massive accuracy leap on unconstrained structure prediction The engine more than doubles AlphaFold 3's accuracy on extremely challenging protein-ligand prediction tasks — including systems far outside the training distribution. 🔹 Best-in-class binding affinity prediction IsoDDE predicts how strongly small molecules bind to targets with accuracy that exceeds gold-standard physics-based methods, at a fraction of the computational cost and time. 🔹 Blind identification of novel binding pockets Even without existing structural data, the engine reveals previously unseen binding sites — just from an amino acid sequence — enabling drug designers to explore entirely new chemical action spaces. 🔹 Expanded support for complex biologics Beyond small molecules, the engine boosts prediction fidelity for...